The Analysis of Influence Factors on Platelet Antibody Production and Clinical Transfusion Effects
-
摘要:
目的 分析昆明医科大学第一附属医院937例患者的血小板抗体检测结果及其影响因素,探究血小板抗体对临床输注效果的影响,为血小板抗体检测的运用价值提供依据,确保血小板的输注更有效、更安全。 方法 2019年6月至2021年4月期间,从申请备血或输血的住院患者中随机收集937例患者的标本,并进行血小板抗体的检测,通过电子病历系统、LIS系统收集患者的一般临床资料。 结果 (1)多次输血患者血小板抗体阳性率为13.23% ,血小板抗体的阳性率和输血的次数有关;(2)血小板抗体检测阳性率女性高于男性(15.95% VS. 10.57% ,P < 0.05);(3)血小板抗体检测阳性率内科患者高于外科患者(16.31% VS. 3.88% ,P < 0.05),其中内科中血小板抗体检测阳性率排前3的科室分别是血液科、急诊科、ICU(19.07% VS. 18.42% VS. 16.95% );(4)对于血液内科患者,化疗的次数、联合使用2类以上化疗药物、既往输注血小板的次数与血小板抗体的检出率显著相关(P < 0.05);(5)血小板输注有效组与无效组的抗体阳性率在统计学上有差异(P < 0.05);(6)血小板抗体中的HLA抗体在非溶血性发热反应中的检出率高达67.85%(19/28)。 结论 (1)血小板抗体的产生与输血次数呈正相关,影响血小板抗体阳性率的因素包括:血小板输注次数、女性孕产史、化疗病人化疗次数、化疗药物使用情况;(2)血小板抗体检测在血小板输注无效的调查研究,血液系统疾病及化疗患者输血疗效评估、输血策略制定、非溶血性发热性输血不良反应的诊断方面具有良好的运用价值;(3)配合性地输注血小板,能使血小板输注更有效。 Abstract:Objective To analyze the platelet antibody detection results and the influence factors of 937 patients in our hospital, explore the impact of platelet antibodies on clinical transfusion effects, provide basis for the application value of platelet antibody detection, and ensure that platelet transfusion is more effective and safe. Methods From June 2019 to April 2021, samples from 937 patients were randomly collected from inpatients who applied for blood preparation or blood transfusion, and platelet antibodies were detected. The patients’ general clinical data were collected through the electronic medical record system and LIS system. Results 1. The positive rate of platelet antibody in patients with multiple transfusions was 13.23% , and the positive rate of platelet antibody correlated with the number of transfusions with statistically significant differences; 2. The positive rate of platelet antibody test was higher in women than in men (15.95% vs 10.57%, P < 0.05); 3. The positive rate of platelet antibody test was higher in medical patient than in surgical patient (16.31% vs 3.88%, P < 0.05), among which the top three department of medicine with positive platelet antibody test rates were the hematology department, the emergency department, and ICU (19.07% vs 18.42% vs 16.95%); 4. For patients in the hematology department, the number of chemotherapy, the combined use of more than 2 types of chemotherapy drugs, and the number of previous transfusion of platelets were significantly correlated with the detection rate of platelet antibodies (P < 0.05); 5. The positive rate of antibodies in the effective and ineffective groups of platelet transfusion was statistically different (P < 0.05); 6. The detection rate of HLA antibodies among platelet antibodies in non-hemolytic febrile reactions was as high as 67.85% (19/28). Conclusion 1. The production of platelet antibody is positively correlated with the number of blood transfusion, and the factors affecting the positive rate of platelet antibodies included: the number of platelet transfusions, female maternal history, the number of chemotherapy treatments in chemotherapy patients, and the use of chemotherapy drugs; 2. The investigation and study of platelet antibody detection has the enormous application value in the ineffectiveness of platelet transfusion, the assessment of transfusion efficacy in patients with hematologic diseases and chemotherapy, the establishment of transfusion strategy, and the diagnosis of non-hemolytic febrile transfusion adverse reactions; 3. The effect of Platelet transfusion can be significantly improved by coordinating platelets transfusion, and can effectively reduce the occurrence of ineffective platelets transfusion. -
表 1 血小板抗体的产生和输血次数的关系[n(%)]
Table 1. The relationship between the production of platelet antibodies and the number of blood transfusions [n(%)]
输血次数 检测人数(n) 阳性人数 0次 194 2(1.03) 1~3次 181 25(13.81) 4~6次 85 13(15.29) 7~9次 83 14(16.87) > 9次 394 70(17.77) 表 2 男性和女性产生血小板抗体的差异[n(%)]
Table 2. Differences in platelet antibody production between men and women [n(%)]
性别 检测人数(n) 阳性人数 χ2 P 男 473 50(10.57) 5.899 0.015* 女 464 74(15.95) *P < 0.05。 表 3 内科患者和外科患者对血小板抗体阳性率的影响[n(%)]
Table 3. The impact of medical patients and surgical patients on the positive rate of platelet antibodies [n(%)]
分类 检测人数(n) 阳性人数 χ2 P 内科 705 115(16.31) 23.498 < 0.001 * 外科 232 9(3.88) *P < 0.05。 表 4 内科患者标本的来源及不同科室血小板抗体检出情况[n(%)]
Table 4. Sources of specimens from medical patients and detection of platelet antibodies in different departments [n(%)]
标本来源 检测人数(n) 阳性人数 ICU 59 10(16.95) 急诊科 38 7(18.42) 血液内科 409 78(19.07) 肿瘤科 32 5(15.63) 神经内科 11 1(9.09) 心内科 24 2(8.33) 消化内科 40 6(15.00) 儿科 39 3(7.69) 风湿免疫科 32 1(3.13) 肾内科 17 2(11.76) 其他 4 0(0.00) 表 5 外科患者标本的来源及不同科室血小板抗体检出情况[n(%)]
Table 5. Sources of surgical patient specimens and detection of platelet antibodies in different departments [n(%)]
标本来源 检测人数(n) 阳性人数 移植科 14 2(14.29) 妇科 9 0(0.00) 产科 122 3(2.46) 骨科 20 2(10.00) 血管外科 11 1(9.09) 神经外科 20 0(0.00) 心胸外科 17 0(0.00) 胃肠科 11 0(0.00) 其它 8 1(12.50) 表 6 血液内科患者特征表及血小板抗体检测情况[n(%)]
Table 6. Characteristics of patients in the department of hematology and the detection of platelet antibodies [n(%)]
患者特征 阳性组(n = 53) 阴性组(n = 304) t/χ2 P 年龄(岁) 46.08 ± 15.94 50.12 ± 12.33 −1.756 0.084 性别(n) 0.531 0.466 男 20 131 女 33 173 病种 10.770 0.056 MDS 14(26.42) 93(30.59) 急淋 9(16.98) 25(8.22) 急非淋 19(35.85) 145(47.70) 慢粒 3(5.66) 22(7.24) MM 4(7.55) 7(2.30) 再障 4(7.55) 12(3.95) 骨髓增生情况 4.579 0.101 增生极度活跃 24(45.28) 177(58.22) 增生活跃 15(28.30) 80(26.32) 增生减低 14(26.42) 47(15.46) 化疗次数 9.453 0.009* < 3次 20(40.82) 153(52.76) 3~6次 16(32.65) 106(36.55) > 6次 13(26.53) 31(10.69) 化疗药物种类 27.655 < 0.001* ≤2类 12(30.77) 187(64.48) > 2类 37(69.23) 103(35.52) 输注次数 7.749 0.021* < 3次 7(134.21) 67(22.04) 3~6次 16(30.19) 126(41.45) > 6 30(56.60) 111(36.51) *P < 0.05。 表 7 血小板输注有效组和无效组的抗体检出情况及特征值比较(
$\bar x \pm s $ )/n(%)Table 7. Comparison of antibody detection and characteristic values between the platelet transfusion effective group and the ineffective group (
$\bar x \pm s $ )/n(%)患者特征 有效组(n = 162) 无效组(n = 341) t/χ2 P 年龄(岁) 43.45 ± 18.72 45.37 ± 22.48 −0.943 0.346 性别
男
女
83(51.23)
79(48.77)
181(53.08)
160(46.92)0.150 0.699 住院天数(d) 10.40 ± 9.43 24.38 ± 18.61 −9.023 < 0.001* 血小板抗体阳性率 9(5.56) 102(29.91) 37.884 < 0.001* CCI(次) 24.40 ± 25.38 14.73 ± 12.76 4.582 < 0.001* 曾输注次数(次) 2 ± 4 8 ± 9 −10.346 < 0.001* *P < 0.05。 表 8 FNHTR患者血小板抗体检测情况[n(%)]
Table 8. Platelet antibody detection status of FNHTR patients [n(%)]
指标 阳性人数 血小板抗体检测 阳性 28(65.12) 阴性 15(34.88) 抗体分类鉴定 HLA 18(64.29) HPA 9(32.14) HLA+HPA 1(3.57) -
[1] 中国医师协会输血科医师分会,中华医学会临床输血学分会. 血小板抗体检测专家共识[J]. 临床输血与检验,2020,22(1):1-5. [2] 陆乐,李平,刘婷婷,等. 不同性别,临床科室患者血小板抗体筛查结果分析[J]. 国际检验医学杂志,2021,42(3):263-265,269. [3] 刘科益,张媛媛,张珍丹. 宁波地区血小板抗体筛查结果的调查和分析[J]. 现代实用医学,2015,27(8):1101-1102. [4] 袁慧铭,邓永乐,陈志龙,等. 血型、性别及输血次数与血小板抗体阳性率关系的探讨[J]. 中国输血杂志,2017,30(7):742-744. [5] 胡维,何巍巍,胡志坚. 血小板抗体检测与患者血小板输注效果的分析[J]. 中国输血杂志,2011,24(5):427-428. [6] 熊婷,周小玉,汪承亚. 血液病患者血小板抗体检测与血小板输注效果的临床分析[J]. 临床血液学杂志:输血与检验,2013,26(1):73-75. [7] 胡立华,罗顺琼,曾淼. 血小板抗体检测对多次输血后血小板输注无效患者的临床价值[J]. 临床医学工程,2020,27(4):433-434. [8] 谢作听,洪俊英,陈钦宏,等. 血小板输注患者血小板抗体筛检及血小板交叉配型情况调查分析[J]. 中国输血杂志,2011,24(4):343-344. [9] 陈曦,王文江,刘娟,等. 联合检测PAIg与CD41+淋巴样小巨核对ITP及MDS鉴别诊断的意义[J]. 现代生物医学进展,2010,10(14):2652-2655. [10] 王涓冬,潘祥林,尹哲,等. 血小板糖蛋白特异性抗体在骨髓增生异常综合征患者中的表达及其意义[J]. 中国实验血液学杂志,2007,15(1):95-98. [11] 谢仁伟,王明泉,李丽群,等. 孕晚期孕妇2038例血小板抗体筛查分析[J]. 福建医药杂志,2016,38(2):98-99. [12] 冯红梅,蔡祥胜,杨兆收,等. 血小板抗体产生的影响因素分析[J]. 广东药科大学学报,2019,35(5):674-678. [13] 聂锋,练正秋,李玲. 血小板抗体检测分析与探讨[J]. 中国实验诊断学,2019,23(12):2052-2054. [14] 李志静. 反复输注血小板的血液病患者输血疗效的分析[J]. 中国输血杂志,2018,31(3):255-257. [15] Abraham A S,Chacko M P,Fouzia N A,et al. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions[J]. Transfusion Medicine,2018,28(5):392-397. doi: 10.1111/tme.12516 [16] Vassallo R R. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients.[J]. Immunohematology,2009,25(3):119-124. doi: 10.21307/immunohematology-2019-244